poisar

Stocks · News reference

Nexalin Says Post Hoc ADAS-Cog Analysis Of Gen-2 SYNC Alzheimer's Trial Found 10 Of 20 Evaluable Active-Arm Patients Improved 4 Or More Points; Findings To Inform Planned U.S. Pilot Study

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NXL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — Nexalin Technology, Inc. (NXL)

    Filed: 2026-09-02 AccNo: 0001829126-26-009659 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    NXL